ALLO - Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 359
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. | Co-Founder & Exec. Chairman | 714.25k | N/A | 1949 |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, Pres, CEO & Director | 1.1M | N/A | 1960 |
| Mr. Joshua A. Kazam | Co-Founder & Director | 711k | N/A | 1977 |
| Dr. Eric Thomas Schmidt Ph.D. | Exec. VP & CFO | 680.12k | N/A | 1970 |
| Mr. Timothy L. Moore Ph.D. | Exec. VP & Chief Technical Officer | N/A | N/A | 1961 |
| Ms. Barbra Sasu | Chief Scientific Officer | N/A | N/A | N/A |
| Mr. Stephen Cheng | Chief Information Officer | N/A | N/A | N/A |
| Ms. Lillian Smith | Interim Gen. Counsel & Compliance Officer | N/A | N/A | 1972 |
| Ms. Christine Cassiano | Chief Communications Officer | N/A | N/A | N/A |
| Ms. Susan R. Lundeen | Chief People Officer | N/A | N/A | 1966 |
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Corporate governance
Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 30 May 2023 is 9. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 8; Compensation: 8.
